MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Начало・Списък с акции・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Отворен

СекторЗдравеопазване

12.54 0.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.18

Максимум

12.73

Ключови измерители
By Trading Economics
Приходи	-445K -19M
Продажби	-3.2M 15M
Марж на печалбата	-123.636
Служители	120
EBITDA	-883K -16M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+48.12% upside

Дивиденти
By Dow Jones
Следващи печалби	6.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-6.1M 364M
Предишно отваряне	11.66
Предишно затваряне	12.54

Настроения в новините

By Acuity

50%

177 / 360 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

5.04 / 5.44 Подкрепа & съпротива

ENANTA PHARMACEUTICALS INC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.01.2026 г., 23:49 ч. UTC

Значими двигатели на пазара

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21.01.2026 г., 21:12 ч. UTC

Значими двигатели на пазара

Automaker Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21.01.2026 г., 20:29 ч. UTC

Значими двигатели на пазара

Chip Makers Gain After Trump Calls Off European Tariffs

21.01.2026 г., 20:04 ч. UTC

Значими двигатели на пазара

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21.01.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21.01.2026 г., 22:39 ч. UTC

Печалби

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.01.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21.01.2026 г., 21:19 ч. UTC

Печалби

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21.01.2026 г., 20:45 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19B

21.01.2026 г., 20:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21.01.2026 г., 20:31 ч. UTC

Пазарно говорене

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21.01.2026 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Was It a 'TACO' Event? -- Market Talk

21.01.2026 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21.01.2026 г., 20:23 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21.01.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21.01.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Group Agrees to Buy Allfunds

21.01.2026 г., 20:08 ч. UTC

Печалби

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21.01.2026 г., 20:03 ч. UTC

Пазарно говорене

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21.01.2026 г., 19:51 ч. UTC

Пазарно говорене

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21.01.2026 г., 19:43 ч. UTC

Пазарно говорене

U.S. Ethanol Production Expected to Slip -- Market Talk

21.01.2026 г., 19:31 ч. UTC

Пазарно говорене

Gold Settles at Fresh All-Time High -- Market Talk

21.01.2026 г., 19:24 ч. UTC

Печалби

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21.01.2026 г., 19:10 ч. UTC

Пазарно говорене

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21.01.2026 г., 18:57 ч. UTC

Пазарно говорене

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

ENANTA PHARMACEUTICALS INC Прогноза

Ценова цел

By TipRanks

48.12% нагоре

12-месечна прогноза

Среден 18.5 USD 48.12%

Висок 20 USD

Нисък 17 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за ENANTA PHARMACEUTICALS INC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на ENANTA PHARMACEUTICALS INC през последните 3 месеца.

Техническа оценка

By Trading Central

5.04 / 5.44Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There are no events.

Настроение

By Acuity

177 / 360 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.